Ignoring threats by communal forces, IAS topper Tina Dabi weds her Muslim friend

Bengaluru, Mar 10: With concerns growing by the day, the Karnataka government is readying three more labs to test throat swab samples.

Currently, only two labs in Bengaluru — National Institute of Virology and Virus Research and Diagnostics Laboratory (VRDL) lab attached to Bangalore Medical College and Research Institute — are categorised biosafety level 2+, a requirement for coronavirus tests.

Now, the government is working on upgrading three more labs, one each in the government medical colleges at Hassan, Mysuru and Shivamogga. “The labs will be ready within one week,” the authorities said.

Currently, the labs are testing only throat swab samples of suspected patients and taking 24 hours to give the results. “A patient’s blood sample will be collected only if he or she tests positive for covid-19 infection in the first throat swab sample.

While earlier the state would send all samples of suspected coronavirus cases to NIV, Pune, the two labs were upgraded to biosafety level 2+ in mid-February.

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.

Bengaluru, Jul 5: A 50-year-old woman with breathing difficulties died on Saturday after a shortage of beds forced 12 hospitals to refuse admission.

Her husband Babu said the family had approached 12 hospitals in three days, including Victoria Hospital and other private facilities, who all slammed their doors on them, citing a shortage of beds. The woman died on Saturday, a few minutes into her admission at KC General Hospital.

Second death 

A 35-year-old man, Manjunath, also died on Saturday after enduring fever for three days and being refused admission at several hospitals due to a shortage of beds.

As his condition worsened, his wife admitted him to a private hospital on Saturday after hours of ordeal. But the man died less than 15 minutes after getting admitted. Hospital authorities took swab samples from the deceased and said the body would be handed over after the test results.

BBMP personnel also failed to shift the body of a Covid-19 patient in Kalasipalya almost a day after the death.

Despite civic workers disinfecting the place, the neighbours were in a state of panic after the body was kept at home.